Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.60 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305521 | 0.84 | SCN9A (0.48) | SCN9ASCN10A | |
| SCHEMBL17582259 | 0.81 | SCN9A (0.56) | SCN9ASCN10ASCN5A | |
| SCHEMBL14944409 | 0.81 | MKNK1 (0.49) | SCN9ASCN10ASCN5A | |
| SCHEMBL303982 | 0.78 | CYP17A1 (0.56) | — | |
| SCHEMBL476793 | 0.77 | CYP1A2 (0.51) | SCN9A | |
| Hydrochloric Acid SCHEMBL304059 | 0.76 | CYP1A2 (0.50) | SCN9A | |
| SCHEMBL17582048 | 0.76 | SCN9A (1.00) | SCN9ASCN10ASCN5A | |
| SCHEMBL1135647 | 0.75 | SCN9A (0.49) | SCN9ASCN10ASCN5A | |
| SCHEMBL29573544 | 0.75 | SCN9A (0.49) | SCN9ASCN10ASCN5A | |
| SCHEMBL4573821 | 0.74 | MAPK14 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783527-B2 | Indazole ureas and method of use | ABBVIE INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3194404-A1 | INDAZOLE UREAS AND METHOD OF USE | AbbVie Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044386-A1 | INDAZOLE UREAS AND METHOD OF USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075692-A1 | Indazole Ureas and Method of Use | ABBVIE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1869003-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108699-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074675-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, MC2R | SCN9A 3494/4885SCN10A 4009/4885SCN5A 2691/4885 |
| US-20160075692-A1 | Indazole Ureas and Method of Use | SCN8A, SCN7A, SCN3A | SCN9A 12/4885SCN10A 38/4885SCN5A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.